UPDATE on RT001 Clinical Trials for PSP

UPDATE on RT001 Clinical Trials for PSP

From Sarah at Retrotope regarding RT001 Clinical Trials for PSP!

Do not lose hope. Retrotope is in the process of developing drugs to treat a variety of neurological diseases, and PSP is a disease that we intend to target. We have treated a few patients in the US with our investigational drug candidate RT001 in a small Expanded Access cohort, and we have seen encouraging results. These results have prompted us to plan a formal clinical trial for PSP and this is likely to begin sometime in summer 2020.

The trial will take place at several centers within the United States. If a patient with PSP meets all trial criteria and is willing and able to travel every few months to a U.S. medical center that is participating in the trial, she or he may be able to enroll in our study.

As the trial start nears, a formal listing regarding the trial and participating clinical trial sites will be posted on https://clinicaltrials.gov/. With your permission, I can additionally add you to my list of patients/families to notify at the appropriate time. Please let me know.

Kind regards,
Sarah

Sarah Endemann, MSc, CCRC
Clinical Coordinator
Retrotope, Inc.
4300 El Camino Real, Ste. 201
Los Altos, CA 94022
Tel: 619.206.5944
Fax: 650.209.5007
sarah@retrotope.com
www.retrotope.com

Back to blog

Leave a public comment:

Please note, comments need to be approved before they are published.

  • Understanding Atypical Parkinsonism: PSP, MSA, CBD, and DLB

    Understanding Atypical Parkinsonism: PSP, MSA, ...

    Laura Louizos

    When we talk about Parkinsonism, most people immediately think of Parkinson's Disease (PD). However, there exists a group of less common disorders known as atypical parkinsonism, each with its unique...

    Understanding Atypical Parkinsonism: PSP, MSA, ...

    Laura Louizos

    When we talk about Parkinsonism, most people immediately think of Parkinson's Disease (PD). However, there exists a group of less common disorders known as atypical parkinsonism, each with its unique...

  • Introducing "Faces and Voices of Atypical Parkinsonism" by CCF

    Introducing "Faces and Voices of Atypical Parki...

    Laura Louizos

    At the Coleen Cunningham Foundation (CCF), we've embarked on a new journey to bring awareness to the lesser-known side of Parkinsonism - the atypical forms. Our latest campaign, "Faces and...

    Introducing "Faces and Voices of Atypical Parki...

    Laura Louizos

    At the Coleen Cunningham Foundation (CCF), we've embarked on a new journey to bring awareness to the lesser-known side of Parkinsonism - the atypical forms. Our latest campaign, "Faces and...

  • Understanding the Stages of Dementia with Lewy Bodies (DLB)

    Understanding the Stages of Dementia with Lewy ...

    Laura Louizos

    Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, motor symptoms similar to Parkinson's disease, and fluctuating alertness. The progression of DLB can...

    Understanding the Stages of Dementia with Lewy ...

    Laura Louizos

    Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, motor symptoms similar to Parkinson's disease, and fluctuating alertness. The progression of DLB can...

  • Understanding the Stages of Multiple System Atrophy (MSA)

    Understanding the Stages of Multiple System Atr...

    Laura Louizos

    Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting several brain regions, resulting in symptoms related to movement, autonomic function, and sleep. Here's how the progression of MSA...

    Understanding the Stages of Multiple System Atr...

    Laura Louizos

    Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting several brain regions, resulting in symptoms related to movement, autonomic function, and sleep. Here's how the progression of MSA...

1 of 4